These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29107073)

  • 1. Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.
    Krupar R; Hautmann MG; Pathak RR; Varier I; McLaren C; Gaag D; Hellerbrand C; Evert M; Laban S; Idel C; Sandulache V; Perner S; Bosserhoff AK; Sikora AG
    Am J Pathol; 2018 Jan; 188(1):72-83. PubMed ID: 29107073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of (18)F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas.
    Baschnagel AM; Wobb JL; Dilworth JT; Williams L; Eskandari M; Wu D; Pruetz BL; Wilson GD
    Radiother Oncol; 2015 Oct; 117(1):118-24. PubMed ID: 26328941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
    Chen YJ; Rau KM; Chien CY; Fang FM; Huang TL; Chiu TJ
    Asian Pac J Cancer Prev; 2011; 12(3):649-55. PubMed ID: 21627359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer.
    Aso T; Matsuo M; Kiyohara H; Taguchi K; Rikimaru F; Shimokawa M; Segawa Y; Higaki Y; Umeno H; Nakashima T; Masuda M
    PLoS One; 2015; 10(3):e0116596. PubMed ID: 25751671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma.
    Oridate N; Homma A; Higuchi E; Suzuki F; Hatakeyama H; Mizumachi T; Furusawa J; Taki S; Furuta Y; Fukuda S
    Auris Nasus Larynx; 2009 Feb; 36(1):57-63. PubMed ID: 18472237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.
    Krupar R; Robold K; Gaag D; Spanier G; Kreutz M; Renner K; Hellerbrand C; Hofstaedter F; Bosserhoff AK
    Virchows Arch; 2014 Sep; 465(3):299-312. PubMed ID: 25027580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
    Watermann C; Pasternack H; Idel C; Ribbat-Idel J; Brägelmann J; Kuppler P; Offermann A; Jonigk D; Kühnel MP; Schröck A; Dreyer E; Rosero C; Nathansen J; Dubrovska A; Tharun L; Kirfel J; Wollenberg B; Perner S; Krupar R
    Clin Cancer Res; 2021 Jan; 27(2):632-644. PubMed ID: 33109740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
    Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients.
    Farnebo L; Tiefenböck K; Ansell A; Thunell LK; Garvin S; Roberg K
    Int J Cancer; 2013 Oct; 133(8):1994-2003. PubMed ID: 23564498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis.
    Wang Y; Li Y; Jiang L; Ren X; Cheng B; Xia J
    Aging (Albany NY); 2021 Feb; 13(5):7284-7299. PubMed ID: 33653965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
    Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
    Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy.
    Camacho M; Piñeiro Z; Alcolea S; García J; Balart J; Terra X; Avilés-Jurado FX; Soler M; Quer M; León X; Vila L
    J Pathol; 2015 Jan; 235(1):125-35. PubMed ID: 25256272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
    Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
    Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
    Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.
    Higuchi E; Oridate N; Homma A; Suzuki F; Atago Y; Nagahashi T; Furuta Y; Fukuda S
    Head Neck; 2007 Oct; 29(10):940-7. PubMed ID: 17563903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
    Ock CY; Keam B; Lim Y; Kim TM; Lee SH; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
    Head Neck; 2016 Feb; 38(2):277-84. PubMed ID: 26104823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years.
    Blatt S; Voelxen N; Sagheb K; Pabst AM; Walenta S; Schroeder T; Mueller-Klieser W; Ziebart T
    Clin Oral Investig; 2016 Nov; 20(8):2097-2104. PubMed ID: 26728026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.
    Pavón MA; Parreño M; León X; Sancho FJ; Céspedes MV; Casanova I; Lopez-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Int J Cancer; 2008 Sep; 123(5):1068-79. PubMed ID: 18546291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.